# A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

> **NCT07702578** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **TScan Therapeutics, Inc.** · enrollment: 310 (estimated)

## Conditions studied

- AML
- MDS

## Interventions

- **DRUG:** TSC-101
- **OTHER:** Control

## Key facts

- **NCT ID:** NCT07702578
- **Lead sponsor:** TScan Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-06-18
- **Primary completion:** 2029-06
- **Final completion:** 2029-06
- **Target enrollment:** 310 (ESTIMATED)
- **Last updated:** 2026-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07702578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07702578, "A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07702578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*